Help patients express priorities clearly
- Trial ID
- NCT04179695
- Official Title
- Optimizing PD Patient's Health Pathways: Favoring Global, Patient Centered Care by a New Communication Aid Tool PARKINSUN
- Goal
- Help patients express priorities clearly
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University Hospital, Lille
- Study Type
- INTERVENTIONAL
- Enrollment
- 120 participants
- Conditions
- Parkinson's Disease
- Interventions
- Consulting with PARKINSUN as communication aid-tool, Consulting without PARKINSUN as communication aid-tool
Plain-Language Summary
The goal is to make Parkinson's care more global and patient centered by improving how patients and clinicians talk about symptoms, priorities, and care plans during visits. The approach uses a communication aid called PARKINSUN during consultations, it prompts and structures patients' symptoms, concerns, and goals, creates a clear summary to help clinicians prioritize issues and guide shared decision making, and is compared to usual consultations without the tool. Adults 18 to 90 with Parkinson's at any stage who can consent and attend visits, have no severe other neurological or psychiatric disease, score above 22 on the MOCA, speak French, and have social security coverage are eligible; people under guardianship or unable to complete the study are excluded.
Locations
- Hopital Roger Salengro, CHU Lille, Lille, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Consulting with PARKINSUN as communication aid-tool. The goal is to make Parkinson's care more global and patient centered by improving how patients and clinicians talk about symptoms, priorities, and care plans during visits. The approach uses a communication aid called PARKINSUN during consultations, it prompts and structures patients' symptoms, concerns, and goals, creates a clear summary to help clinicians prioritize issues and guide shared decision making, and is compared to usual consultations without the tool. Adults 18 to 90 with Parkinson's at any stage who can consent and attend visits, have no severe other neurological or psychiatric disease, score above 22 on the MOCA, speak French, and have social security coverage are eligible; people under guardianship or unable to complete the study are excluded.
- Who can participate?
- Participants must be between 18 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 6 years and 4 months.